Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Yong-Chen Lu to Neoplasms

This is a "connection" page, showing publications Yong-Chen Lu has written about Neoplasms.

 
Connection Strength
  
 
 
2.514
  
  1. Kirkpatrick C, Lu YW. Deciphering CD4+ T cell-mediated responses against cancer. Mol Carcinog. 2024 Jul; 63(7):1209-1220.
    View in: PubMed
    Score: 0.467
  2. Pasetto A, Lu YC. Single-Cell TCR and Transcriptome Analysis: An Indispensable Tool for Studying T-Cell Biology and Cancer Immunotherapy. Front Immunol. 2021; 12:689091.
    View in: PubMed
    Score: 0.381
  3. Lu YC, Wang XJ. Harnessing the power of the immune system in cancer immunotherapy and cancer prevention. Mol Carcinog. 2020 07; 59(7):675-678.
    View in: PubMed
    Score: 0.354
  4. Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, Yao X, Li YF, Robbins PF, Feldman SA, van der Bruggen P, Klebanoff CA, Goff SL, Sherry RM, Kammula US, Yang JC, Rosenberg SA. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. J Clin Oncol. 2017 Oct 10; 35(29):3322-3329.
    View in: PubMed
    Score: 0.293
  5. Lu YC, Robbins PF. Targeting neoantigens for cancer immunotherapy. Int Immunol. 2016 07; 28(7):365-70.
    View in: PubMed
    Score: 0.269
  6. Lu YC, Robbins PF. Cancer immunotherapy targeting neoantigens. Semin Immunol. 2016 02; 28(1):22-7.
    View in: PubMed
    Score: 0.260
  7. Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, Rosenberg SA, Robbins PF. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res. 2014 Jul 01; 20(13):3401-10.
    View in: PubMed
    Score: 0.236
  8. Kim SP, Vale NR, Zacharakis N, Krishna S, Yu Z, Gasmi B, Gartner JJ, Sindiri S, Malekzadeh P, Deniger DC, Lowery FJ, Parkhurst MR, Ngo LT, Ray S, Li YF, Hill V, Florentin M, Masi RV, Paria BC, Levin N, Bera A, Hedges EA, Choi A, Chatani PD, Parikh AY, Levi S, Seitter S, Lu YC, Zheng Z, Prickett TD, Jia L, Hernandez JM, Hoang CD, Robbins PF, Goff SL, Sherry RM, Yang JC, Rosenberg SA. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors. Cancer Immunol Res. 2022 08 03; 10(8):932-946.
    View in: PubMed
    Score: 0.103
  9. Lowery FJ, Krishna S, Yossef R, Parikh NB, Chatani PD, Zacharakis N, Parkhurst MR, Levin N, Sindiri S, Sachs A, Hitscherich KJ, Yu Z, Vale NR, Lu YC, Zheng Z, Jia L, Gartner JJ, Hill VK, Copeland AR, Nah SK, Masi RV, Gasmi B, Kivitz S, Paria BC, Florentin M, Kim SP, Hanada KI, Li YF, Ngo LT, Ray S, Shindorf ML, Levi ST, Shepherd R, Toy C, Parikh AY, Prickett TD, Kelly MC, Beyer R, Goff SL, Yang JC, Robbins PF, Rosenberg SA. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science. 2022 02 25; 375(6583):877-884.
    View in: PubMed
    Score: 0.100
  10. Yao X, Ahmadzadeh M, Lu YC, Liewehr DJ, Dudley ME, Liu F, Schrump DS, Steinberg SM, Rosenberg SA, Robbins PF. Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood. 2012 Jun 14; 119(24):5688-96.
    View in: PubMed
    Score: 0.051
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.